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ABSTRACT
Background/aims ONO-9054 is being developed for
the reduction of intraocular pressure (IOP) in patients
with ocular hypertension (OHT) and open-angle
glaucoma (OAG). This study compared the novel dual
EP3/FP agonist ONO-9054 with the FP agonist Xalatan.
Methods Adults (n=123) with bilateral mild/moderate
OAG or OHT, with unmedicated IOP of ≥24 mm Hg at
8:00 hours, ≥21 mm Hg at 10:00 hours and
≤36 mm Hg, were randomised 1:1 to receive ONO-9054
(0.003%, 30 μg/mL) or Xalatan (0.005%, 50 μg/mL)
once daily for 28 days.
Results Day 29 mean diurnal IOP was −7.2 mm Hg
for ONO-9054 vs −6.6 mm Hg for Xalatan. At
08:00 hours, the IOPs were comparable, and at all later
time points the decrease in IOP was greater for ONO-
9054. On day 29, the odds of a mean IOP reduction of
≤−25%, ≤−30% and ≤−35% for ONO-9054 were
2.39, 2.37 and 4.85 times more, respectively, than the
odds for Xalatan (p<0.05, post hoc analyses). The
percentage of subjects achieving target IOPs on day 29
(≤17, ≤16 and ≤15 mm Hg) was greater for ONO-
9054 than for Xalatan; the odds of achieving an IOP
≤15 mm Hg for ONO-9054 were 2.4 times more than
the odds for Xalatan (p<0.01, post hoc analysis).
Conclusions Subjects randomised to receive ONO-
9054 were more likely to achieve a greater per cent
reduction in IOP and were more likely to achieve target
IOPs than those receiving Xalatan. The effects of ONO-
9054 in reducing IOP appear to persist longer than
those of Xalatan.
Trial registration number NCT02083289, Results.
INTRODUCTION
Open-angle glaucoma (OAG), a chronic ocular
disease characterised by progressive optic neur-
opathy and visual field loss, is the second most
common cause of blindness.1 Elevated intraocular
pressure (IOP) is a major risk factor for develop-
ment and progression of OAG. Reduction of IOP
prevents or delays onset of OAG in patients with
ocular hypertension (OHT)2 and slows progression
in both normal and elevated pressure OAG.3–7
Prostaglandin analogues (PGAs) are commonly
prescribed IOP-lowering medications targeting the
prostanoid F (FP) receptor which lower IOP mainly
by increasing the outflow of aqueous humour, pri-
marily through the uveoscleral pathway.8–10
ONO-9054 (sepetaprost) is a novel dual EP3 and
FP agonist.11 In monkeys, more potent and longer
lasting IOP-lowering effects are seen compared
with existing PGAs;11 this reduction is via increase in
trabecular and uveoscleral outflow.12 It was hypothe-
sised that dual agonist activity might provide a
greater and more sustained reduction in IOP.
ONO-9054 is safe and well tolerated in normo-
tensive adults and in those with OHT and OAG at
doses up to 30 mg/mL.13–15 A single dose of
ONO-9054 reduced IOP by up to 28.23% in
normotensive, healthy adults.13 After 14 days of
dosing in adults with OHT or OAG, the peak
reduction in IOP was from 23.3 to 15.1 mmHg at
1 hour post final dose with a sustained effect to at
least 24 hours post final dose, with similar effects
achieved from morning and evening dosing.13 15
The purpose of this study was to compare the EP3/
FP agonist ONO-9054 with the FP agonist Xalatan;
this manuscript reports the results of this trial.
MATERIALS AND METHODS
Subjects
Men and women aged 18–85 years with a diagnosis
of bilateral OHT or mild to moderate OAG; an
unmedicated IOP ≥24 mm Hg at 08:00 hours,
≥21 mm Hg at 10:00 hours and ≤36 mm Hg;
central corneal thickness of 500–620 μm; best-
corrected visual acuity (BCVA) of at least +0.7
LogMar and ocular cup-to-disc ratio ≤0.8.
Exclusion criteria included: a history of severe
ocular trauma; a history of angle closure or current
angle of ≤2 (Shaffer scale); intraocular or ocular
laser surgery within 3 months; refractive surgery
within 6 months.
Study design
This phase II, randomised, double-masked, active
comparator study took place between 02 June and
02 December 2015 at nine clinical sites in the USA
(NCT02083289). The protocol was approved by
institutional review boards (IRBs), and the study was
conducted in accordance with the ethical principles
of Good Clinical Practice and the Declaration of
Helsinki. All subjects provided written, informed
consent. Subjects were required to attend seven
study visits (eligibility review 1 (ER1; day −45 to
day −6), eligibility review 2 (ER2; day −5±2 days),
eligibility review 3 (day 1, used as baseline), day 8
±2 days, day 15±2 days, day 29±2 days and day 35
±3 days (follow-up visit)).
Subjects were randomised 1:1 to ONO-9054
30 μg/mL (0.003%) or Xalatan (0.005%) for
28 days by IWRS. Stratification was by site and
baseline IOP (day 1, 08:00 hours) as either <26 or
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≥26 mm Hg. Study drug was self-administered as one drop
(approximately 30 μL) in each eye once daily at 22:00±2 hours.
Xalatan was provided in the US commercial bottle, overlabelled
to maintain the masking, and ONO-9054 was supplied in a
polypropylene bottle with polyethylene nozzle and cap. Both
were dispensed and stored in plastic containers to maintain
masking.
Pharmacodynamics
IOP readings were performed using Goldmann applanation
tonometry with masked observer and recorder. IOP was assessed
on days 1, 8, 15 and 29 at 08:00, 10:00, 12:00, 16:00 hours
and at 20:00 hours on days 1 and 29. A single IOP measure-
ment was taken at an unspecified time on day 35.
Safety and tolerability
Vital signs, safety laboratory evaluations and concomitant
medication data were recorded throughout the study; physical
examinations were conducted throughout the study, and
treatment-emergent adverse events (TEAEs) were recorded from
days 1 to 35. Ocular safety assessment included BCVA, symp-
tomatology, pupillometry and slit-lamp examinations, which
were conducted at ER1 and days 1, 8, 15, 29 and 35.
Pachymetry was measured at ER1, ER2 and days 29 and 35.
Indirect ophthalmology examination was conducted at ER1,
ER2 and days 15, 29 and 35. Optical coherence tomography
images were captured at ER1 and on days 29 and 35 and read
both by the investigator and a central reader. Hyperaemia was
evaluated by comparison with standardised photographs (Ora
Calibra Redness Scale 6.b (0–3 scale), used under licence from
Ora, Andover, Massachusetts, USA)) on days 1, 8, 15, 29 and
35. Symptomatology (photophobia, itching, tearing, dryness
and discharge as 0 (absent), 1 (mild), 2 (moderate), 3 (severe
with stinging or burning) or 4 (severe with blurred or dim
vision)) was assessed on days 1, 8, 15, 29 and 35.
Statistics
The study was powered (≥80%) to detect a difference between
treatments at the 5% significance level. The power was esti-
mated based on the assumption that the true treatment differ-
ence between ONO-9054 and Xalatan was not <2.0 mm Hg
and the SD was no more than 3.5 mm Hg. The safety analysis
set (SAF) included all subjects who received study medication
and was used for analysis of safety data. The per protocol set
(PPS) included all subjects who had no major protocol violation
(determined prior to unmasking), compliance >80%, treatment
duration ≥21 days and IOP assessments on days 1 and 29; PPS
was used for analysis of pharmacodynamic data.
Statistical output was generated using SAS V.9.2 (SAS, Cary,
North Carolina, USA.). The primary analysis was mean change
from baseline (CFB), where day 1 is baseline, in mean diurnal IOP
on day 29 (08:00, 10:00, 12:00 and 16:00 hours) using both ana-
lysis of covariance with the mean baseline diurnal IOP for the four
time points on day 1 and study site as covariates, and also by the
Student’s t-test. Diurnal IOP secondary endpoints were analysed
for actual and percentage change using mixed model repeat mea-
sures. Post hoc analyses were conducted to better understand and
interpret the data and support the prospective analyses; these used
the same methods as prospective analyses. For IOP analyses, data
from the eligible eye were used, defined as day 1 IOP ≥24 mm Hg
at 08:00 hours and ≥21 mmHg at 10:00 hours; when both were
eligible, that with the higher IOP at 08:00 hours on day 1 was
used, and if both had the same IOP at 08:00 hours on day 1, the
right eye was the eligible eye.
The primary endpoint was change in mean diurnal IOP
(average of 08:00, 10:00, 12:00 and 16:00 hours) on day 29.
Secondary and post hoc analyses included comparisons of
diurnal IOP at other combinations of time points, individual
time points, per cent responders and treatment response rates to
target IOPs.
RESULTS
Disposition, demographics and baseline characteristics
One hundred and twenty-three subjects were randomised (62 to
ONO-9054 and 61 to Xalatan). The mean age was 64.5 years,
and 54.5% of subjects were female. The population was 72.4%
white, 25.2% black or African–American and 2.4% Asian. The
demographic profile was similar in the two treatment groups.
The majority of subjects (56.1%) had not received any previous
glaucoma medications, but in those that had, the incidence was
similar between the groups. Approximately half the subjects had
the right eye designated as the eligible eye (50.4%), with the
incidence of eligible right and left eyes being similar between
the groups. More subjects had OAG than OHT (68.3% vs
31.7%), and more ONO-9054 subjects had OHT compared
with Xalatan (37.1% vs 26.2%). The mean baseline IOP and
number of subjects with baseline diurnal IOP <26 and
≥26 mm Hg were similar between groups.
One subject from the ONO-9054 group withdrew due to AEs
of moderate conjunctival hyperaemia (considered definitely
related to treatment) starting 2 days after the start of treatment,
and mild discomfort with blinking (considered probably related
to treatment) starting 3 days after the start of treatment. One
subject from the Xalatan group was withdrawn by the site after
22 days of treatment because blood for safety analyses could not
be obtained. More ONO-9054 subjects were excluded from the
PPS (14.5%) compared with that of Xalatan (4.9%), with more
ONO-9054 subjects excluded due to compliance issues (6.5%
for ONO-9054 vs 0% for Xalatan).
Pharmacodynamics
Both groups showed decreases in diurnal IOP from day 8 (the
first on-treatment assessment), which were maintained through-
out the dosing period (figure 1 and table 1). ONO-9054 achieved
a greater reduction in mean diurnal IOP (08:00, 10:00, 12:00
and 16:00 hours; −7.2 mmHg vs −6.6 mmHg) compared with
Xalatan, but this was not statistically significant at the 5% level.
Mean CFB in IOP for ONO-9054 was numerically superior to
that for Xalatan at all time points, with IOPs comparable at
08:00 hours and a greater decrease in IOP for ONO-9054 com-
pared with that for Xalatan later in the day (figure 1 inset and
table 1). Statistical significance was achieved at some individual
time points and also for day 29 at 10:00, 12:00, 16:00 and
20:00 hours combined (p<0.05, post hoc analysis). SDs for
ONO-9054 data were generally higher than those for Xalatan.
ONO-9054 subjects were more likely to achieve a greater
response to treatment (figure 2). On day 29, the odds of a mean
IOP reduction of ≤−25%, ≤−30% and ≤−35% for ONO-9054
were 2.39, 2.37 and 4.85 times more, respectively, than the
odds for Xalatan (p<0.05, post hoc analyses). The odds of an
IOP reduction of ≤−30% and ≤−40% for ONO-9054 subjects
were 1.9 and 2.4 times more, respectively, than the odds for
Xalatan across all time points from days 8, 15 and 29 combined
(p<0.001, post hoc analyses). The percentage of subjects achiev-
ing target IOP on day 29 (≤17, ≤16 and ≤15 mm Hg) was
greater for ONO-9054 than that for Xalatan (table 2), and the
odds of achieving a target IOP≤15 mm Hg for ONO-9054 were
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2.4 times more than the odds for Xalatan (p<0.01, post hoc
analysis; ≤17 and ≤16 analyses not performed).
Safety and tolerability
There were 37 AEs in 22 ONO-9054 subjects and 35 AEs in
18 Xalatan subjects (table 3); all were mild or moderate in
intensity. The most common system organ class (SOC) was
eye disorders, with the incidence of TEAEs in this SOC
being higher for ONO-9054 compared with that for Xalatan
(31 events compared with 25). The most common TEAE
was conjunctival hyperaemia. One unrelated serious adverse
event (non-arteritic ischaemic optic neuropathy, reported on
day 28) occurred in a subject randomised to receive
ONO-9054.
Figure 1 Time-matched change from
baseline for mean intraocular pressure
(IOP) (mm Hg) following 8, 14 and 28
consecutive days of dosing for subjects
receiving ONO-9054 30 μg/mL or
Xalatan 10 μg/mL (±SD). Subjects
receiving ONO-9054 achieved a greater
reduction in IOP at all time points.
Inset: Mean IOP (mm Hg) for subjects
receiving ONO-9054 30 μg/mL or
Xalatan 10 μg/mL (±SD) following 28
consecutive days of dosing. Subjects
receiving ONO-9054 displayed a
similar reduction in IOP at 08:00 hours
and a greater reduction in IOP at all
other time points suggesting a more
sustained response. *p<0.05 (10:00,
12:00, 16:00, 20:00 hours post hoc
analysis).
Table 1 Diurnal and mean diurnal (08:00, 10:00, 12:00, and 16:00 hours) IOP (mm Hg) and change from baseline for time-matched time
points in study eye (PPS)
ONO-9054 (N=53) Xalatan (N=58)
Day Time
Observed value,
mm Hg
Change from
baseline, mm Hg
% Change from
baseline
Observed value,
mm Hg
Change from
baseline, mm Hg
% Change from
baseline
Day 1
baseline
08:00 26.9 (3.2) 26.6 (2.5)
10:00 24.7 (2.8) 24.8 (2.8)
12:00 23.9 (3.1) 24.2 (3.1)
16:00 23.1 (3.2) 23.6 (3.6)
20:00 21.9 (3.6) 22.4 (3.4)
Mean diurnal
IOP
24.6 (2.4) 24.8 (2.6)
Day 8 08:00 18.5 (3.4) −8.5 (4.1) −31.0 (13.1) 18.6 (3.1) −8.0 (2.9) −30.0 (10.0)
10:00 17.1 (3.2) −7.6 (3.3) −30.5 (12.2) 18.0 (3.2) −6.8 (3.0) −27.3 (11.2)
12:00 17.0 (3.4) −6.9 (3.6) −28.3 (13.5) 17.9 (2.8) −6.3 (3.7) −25.3 (13.1)
16:00 16.6 (2.9) −6.5 (3.4) −27.3 (12.8) 18.0 (3.1) −5.7 (3.1) −23.3 (11.7)
Mean diurnal
IOP
17.3 (2.9) −7.4 (2.9) −29.7 (10.7) 18.1 (2.7) −6.7 (2.5) −26.8 (9.0)
Day 15 08:00 18.5 (3.6) −8.5 (4.3) −30.9 (13.9) 18.7 (3.4) −7.9 (3.2) −29.7 (11.3)
10:00 17.3 (3.4) −7.5 (3.7) −29.8 (13.6) 17.9 (2.8) −6.9 (3.2) −27.2 (11.5)
12:00 17.3 (3.8) −6.6 (3.7) −27.2 (13.7) 18.0 (2.4) −6.2 (2.7) −25.1 (9.2)
16:00 16.7 (2.9) −6.4 (3.3) −27.1 (12.4) 18.5 (2.8) −5.1 (3.2) −20.7 (12.0)
Mean diurnal
IOP
17.4 (3.1) −7.2 (3.0) −29.2 (11.2) 18.3 (2.4) −6.5 (2.4) −26.0 (8.4)
Day 29 08:00 18.7 (3.3) −8.3 (3.6) −30.4 (11.3) 18.6 (3.2) −8.1 (2.4) −30.4 (8.9)
10:00 17.2 (3.4) −7.5 (3.6) −30.0 (13.4) 18.2 (2.9) −6.6 (3.0) −26.5 (10.9)
12:00 17.3 (3.3) −6.7 (3.8) −27.2 (14.1) 18.1 (2.9) −6.1 (3.1) −24.8 (11.0)
16:00 16.8 (3.0) −6.2 (3.8) −26.1 (14.8) 17.9 (2.7) −5.7 (3.3) −23.3 (12.0)
20:00 16.7 (3.3) −5.2 (3.4) −23.2 (12.1) 17.9 (2.8) −4.5 (3.4) −19.0 (13.0)
Mean diurnal
IOP
17.5 (2.9) −7.2 (3.1) −28.8 (11.4) 18.2 (2.5) −6.6 (2.0) −26.7 (7.3)
Day 35
follow-up
23.3 (3.8) 23.1 (4.2)
Data are mean±SD.
IOP, intraocular pressure; N, number of subjects; PPS, per protocol set.
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Hyperaemia scores and CFB were similar between
ONO-9054 and Xalatan groups (mean (minimum, maximum)
CFB at day 29 was 0.19 (−1.00, 2.50) for ONO-9054 vs 0.21
(−0.50, 1.00) for Xalatan); however, the number of hyperaemia
adverse events (AEs) for ONO-9054 was higher than that for
Xalatan (19.4% of ONO-9054 vs 8.2% of Xalatan subjects).
Hyperaemia AEs resolved without sequelae, and symptoms
returned to baseline levels by follow-up. Symptomatology scores
were similar between treatment groups at baseline, and most
subjects showed no change in scores during the study.
No notable differences were seen between treatment groups
for vital signs, laboratory or ocular safety parameters, and no
observations were seen that were indicative of a harmful ocular
effect occurring with either treatment.
DISCUSSION
The purpose of this investigation was to compare the EP3/FP
agonist ONO-9054 with the FP agonist Xalatan. Xalatan was
selected as the comparator since there is evidence that Xalatan
reduces IOP more than the generic latanoprost16 17 and thus
represents the most appropriate and significant comparative
standard. In addition, as multiple generic brands of latanoprost
are available, Xalatan was used to allow consistency of
comparison.
Slightly more subjects with OHT were randomised to
ONO-9054 compared with Xalatan; the significance with
respect to response to treatment is unclear. During the masked
data review, a greater number of ONO-9054 subjects were
excluded from PPS due to low compliance, as measured by a
paper diary. ONO-9054 and ONO-AG-367 are cleared from
plasma rapidly; so, there would have been no measurable levels
following the evening dosing. Potentially, ease of use of the dif-
ferent shaped bottles could have impacted dosing compliance.
The CFB in mean diurnal IOP (average of 08:00, 10:00,
12:00 and 16:00 hours) was greater for ONO-9054
(−7.2 mm Hg) compared with that for Xalatan (−6.6 mm Hg).
The reduction in IOP for Xalatan was within the wide range of
values previously reported for latanoprost,17–22 although direct
comparison between studies is challenging due to differing
dosing durations, IOP measurement times, inclusion and exclu-
sion criteria and baseline IOP. In addition, it is not always clear
whether data for Xalatan or for generic latanoprost are being
reported.
These data suggest that following evening dosing, both treat-
ments were similarly effective at 08:00 hours, but there was a
greater and more prolonged effect for ONO-9054 compared
with that for Xalatan throughout the day. The observed sus-
tained response was predicted from preclinical and clinical
data11 13 15 however, considering the rapid clearance from
plasma of the active metabolite ONO-AG-367,13 the mechanism
for this sustained response is unknown. Nonetheless, this sus-
tained reduction of IOP may be beneficial for subjects with
OAG and OHT.
Subjects with higher baseline IOP have previously been
shown to respond better to PGAs;18 therefore, baseline IOP was
used both as a stratification factor and a covariate in analyses to
avoid bias. However, in this study, there was no evidence of a
greater treatment difference for ONO-9054 versus Xalatan in
subjects with a higher baseline IOP.
ONO-9054 subjects had a greater response to treatment, with
more ONO-9054 subjects having a reduction in IOP of ≤−25%,
≤−30%, ≤−35% and ≤−40% from baseline and achieving an
absolute IOP value ≤17, 16 and 15 mm Hg. Reduction in IOP is
a recognised goal in the treatment of OAG and OHT and corre-
lates with long-term outcomes in glaucoma;3–7 therefore, it is
considered that there is a potential clinical benefit from treatment
with ONO-9054, particularly in patients with a high risk of pro-
gression requiring a large initial reduction in IOP. Since the
extent of reduction in IOP was evident from the first IOP meas-
urement day, it is possible to identify responders and non-
responders rapidly even in the absence of a method to predict
response. There was a greater range of responses to ONO-9054
than to Xalatan, with some subjects (∼10%) being low
Figure 2 Per cent change from baseline in diurnal intraocular
pressure (IOP) at day 29 (08:00, 10:00. 12:00, 16:00 and 20:00 hours)
for ONO-9054 and Xalatan. The odds of a mean IOP reduction of
≤−25%, ≤−30% and ≤−35% for ONO-9054 were 2.39, 2.37 and
4.85 times more, respectively, than the odds for Xalatan (p<0.05, post
hoc analyses). The odds of an IOP reduction of ≤−30% and ≤−40%
for ONO-9054 subjects were 1.9 and 2.4 times more, respectively, than
the odds for Xalatan across all time points from days 8, 15 and 29
combined (*p<0.001, post hoc analyses).
Table 2 Number and per cent of subjects achieving a target IOP of ≤17, ≤16 and ≤15 mm Hg on day 29 (PPS)
Number (per cent) of subjects achieving target response
Target IOP, mm Hg 08:00 10:00 12:00 16:00 20:00
≤17 ONO-9054
Xalatan
21 (39.6)
23 (39.7)
29 (54.7)
24 (41.4)
26 (49.1)
27 (46.6)
33 (62.3)
31 (53.4)
31 (58.5)
24 (41.4)
≤16 ONO-9054
Xalatan
14 (26.4)
15 (25.9)
23 (43.4)
17 (29.3)
21 (39.6)
17 (29.3)
25 (47.2)
17 (29.3)
27 (50.9)
16 (27.6)
≤15* ONO-9054
Xalatan
7 (13.2)
7 (12.1)
17 (32.1)
9 (15.5)
17 (32.1)
10 (17.2)
18 (34.0)
6 (10.3)
22 (41.5)
10 (17.2)
Data are mean±SD. The percentage of subjects achieving target IOP on Day 29 (≤17, ≤16 and ≤15 mmHg) was greater for ONO-9054 than Xalatan, and the odds of achieving
a target IOP ≤15 mmHg for ONO-9054 were 2.4 times more than the odds for Xalatan (*p<0.01, post hoc analysis; ≤17 and ≤16 analyses not performed).
IOP, intraocular pressure; PPS, per protocol set.
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responders to ONO-9054, while others were very high respon-
ders. There is currently no explanation for this; although, inter-
estingly, low responders to ONO-9054 had no increases from
baseline in hyperaemia score, which may indicate low
compliance.
Although the hyperaemia scores were similar in both groups,
the incidence of hyperaemia AEs was higher in the ONO-9054
group. The reporting of hyperaemia as an AE was inconsistent
across sites and did not correlate to either the hyperaemia score
or CFB, making these AE data difficult to interpret.
CONCLUSION
ONO-9054 and Xalatan were both safe and well tolerated.
ONO-9054 subjects were more likely to achieve a significantly
greater per cent reduction in IOP than those receiving Xalatan
and were more likely to achieve target IOPs. Additionally, the
effects of ONO-9054 in reducing IOP appear to persist longer
than those of Xalatan; however, further study is required. This
study supports further development of ONO-9054 for treat-
ment of OAG and OHT.
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Table 3 Treatment emergent adverse events (TEAEs) reported by
>1 subject
ONO-9054
30 μg/mL (0.003%)
(N=62)
Xalatan 0.005%
(N=61)
System organ class
preferred term Events Subjects (%) Events Subjects (%)
Total number of TEAEs 37 22 (35.5) 35 18 (29.5)
Eye disorders 31 21 (33.9) 25 14 (23.0)
Conjunctival hyperaemia 14 12 (19.4) 5 5 (8.2)
Vision blurred 3 3 (4.8) 0 0
Abnormal sensation in eye 2 2 (3.2) 2 2 (3.3)
Visual acuity reduced 2 2 (3.2) 1 1 (1.6)
Punctate keratitis 2 2 (3.2) 3 3 (4.9)
Dry eye 1 1 (1.6) 2 2 (3.3)
Eye discharge 1 1 (1.6) 3 2 (3.3)
Eye pruritus 0 0 2 2 (3.3)
Episcleral hyperaemia 0 0 2 2 (3.3)
General disorders and
administrative site conditions
2 2 (3.2) 6 6 (9.8)
Instillation site pain 2 2 (3.2) 5 5 (8.2)
Infections and infestations 1 1 (1.6) 4 3 (4.9)
Nasopharyngitis 0 0 2 2 (3.3)
N, the number of subjects in the analysis set.
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